# GVAX vs. Placebo for MDS/AML After Allo HSCT

> **NCT01773395** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 123 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **BIOLOGICAL:** GVAX
- **BIOLOGICAL:** Placebo Vaccine
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplant
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **DRUG:** Tacrolimus
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01773395
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01-08
- **Primary completion:** 2020-12-11
- **Final completion:** 2021-11-24
- **Target enrollment:** 123 (ACTUAL)
- **Why stopped:** Recommendation by the Data and Safety Monitoring Board due to efficacy concerns
- **Last updated:** 2022-07-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773395, "GVAX vs. Placebo for MDS/AML After Allo HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01773395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*